Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 2:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 3,785 matching trials from the live ClinicalTrials.gov search.
Conditions
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Interventions
Laromustine (VNP40101M) and Ara-C
Drug
Lead sponsor
Viron Therapeutics Inc
Industry
Eligibility
60 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Conditions
B-cell Lymphoma, Burkitt Lymphoma
Interventions
Etoposide, Doxorubicin, Cyclophosphamide, Rituximab, Vincristine, Prednisone, Loncastuximab Tesirine 0.075 mg/kg by IV, Loncastuximab tesirine 0.12 mg/kg by IV, Loncastuximab tesirine 0.15 mg/kg by IV
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Dallas, Texas • Madison, Wisconsin • Milwaukee, Wisconsin
Conditions
Healthy Volunteers
Interventions
TAK-279, TAK-279 Placebo, Moxifloxacin, Moxifloxacin Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Tempe, Arizona
Conditions
Meningitis, Neoplasms
Interventions
Gemcitabine
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
3 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
5
States / cities
Bethesda, Maryland • Pittsburgh, Pennsylvania • Houston, Texas + 1 more
Conditions
Melanoma
Interventions
APX005M, Pembrolizumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Houston, Texas
Conditions
Acute Myeloid Leukemia
Interventions
G-CSF, Cytarabine, Fludarabine, Donor Natural Killer (NK) cells, ALT-801
Drug · Biological
Lead sponsor
Altor BioScience
Industry
Eligibility
2 Years to 59 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Houston, Texas
Conditions
Malaria
Interventions
Mefloquine, Control
Drug · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Silver Spring, Maryland
Conditions
Multiple Myeloma
Interventions
Elotuzumab (HuLuc63)
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
8
States / cities
Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 5 more
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
capecitabine, irinotecan hydrochloride, oxaliplatin
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Progressive Multifocal Leukoencephalopathy, Multiple Sclerosis, Other Neuroinflammatory Diseases With BBB Leakage
Interventions
89 Zr-Df-crefmirlimab
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 120 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Neurocomputational Dynamics of Cooperation

NCT07759973
Conditions
Social Cognition, Personality Disorder, Mental Health, Interpersonal Conflict
Interventions
Social Learning Task Battery, Clinical Cohort, Social Learning Task Battery, Online Cohort
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 100 Years
Enrollment
1,612 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Healthy Volunteers
Interventions
GC021109, Placebo
Drug · Other
Lead sponsor
GliaCure, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Neptune City, New Jersey
Conditions
Atopic Dermatitis
Interventions
Crisaborole ointment, 2%, Hydrocortisone butyrate cream, 0.1%, Pimecrolimus cream, 1%, Crisaborole Vehicle
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
10
States / cities
Bryant, Arkansas • Encinitas, California • Orange Park, Florida + 7 more
Conditions
Solid Tumor
Interventions
Selinexor, Acetaminophen
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
4
States / cities
Tampa, Florida • Detroit, Michigan • New York, New York + 1 more
Conditions
SCN2A Encephalopathy, SCN8A Encephalopathy
Interventions
PRAX-562
Drug
Lead sponsor
Praxis Precision Medicines
Industry
Eligibility
1 Year to 18 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
Atlanta, Georgia • Chicago, Illinois • Minneapolis, Minnesota + 1 more
Conditions
Multiple Myeloma
Interventions
Thalidomide+Melphalan +Bortezomib+stem cell transplant
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Hackensack, New Jersey
Conditions
Short Bowel Syndrome
Interventions
Teduglutide 0.05mg/kg, Teduglutide 0.025 mg/kg, Standard of Care
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
0 Years to 17 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
18
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 14 more
Conditions
Cancer
Interventions
Bone scan, 99mTc-methyl diphosphonate, Positron Emission Tomography (PET) scan, 18F-Fludeoxyglucose (18F-FDG), Computed Tomography (CT) scan, 18F-Sodium Fluoride (18F-NaF), Whole Body Magnetic Resonance Imaging (WB-MRI) scan, Gadopentetate dimeglumine, Gadofosveset, Gadobutrol
Procedure · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
1
States / cities
Stanford, California
Completed Phase 1 Interventional Results available

MIBG With Dinutuximab +/- Vorinostat

NCT03332667
Conditions
Neuroblastoma
Interventions
131I-MIBG, Dinutuximab, Vorinostat, Sargramostim, Potassium Iodide
Radiation · Drug
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
1 Year to 30 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 9 more
Conditions
Healthy
Interventions
TD-5202, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
19 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Lincoln, Nebraska
Conditions
Malignancies Multiple
Interventions
BMS-986205, Itraconazole, Rifampin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 50 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Austin, Texas
Conditions
Rheumatoid Arthritis
Interventions
TCK-276, TCK-276 Placebo
Drug
Lead sponsor
Teijin America, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Tustin, California • Doral, Florida • Miami, Florida + 3 more
Terminated Phase 1Phase 2 Interventional Results available

Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors

NCT04106492
Conditions
Cancer
Interventions
SQ3370
Drug
Lead sponsor
Shasqi, Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
7
States / cities
Duarte, California • Palo Alto, California • Santa Monica, California + 4 more
Conditions
Schizophrenia, Major Depressive Disorder (MDD), Bipolar Disorder
Interventions
SEP-380135, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Los Alamitos, California